KR102717665B1 - 자가면역 미세혈관 장애의 치료 방법 - Google Patents

자가면역 미세혈관 장애의 치료 방법 Download PDF

Info

Publication number
KR102717665B1
KR102717665B1 KR1020207003115A KR20207003115A KR102717665B1 KR 102717665 B1 KR102717665 B1 KR 102717665B1 KR 1020207003115 A KR1020207003115 A KR 1020207003115A KR 20207003115 A KR20207003115 A KR 20207003115A KR 102717665 B1 KR102717665 B1 KR 102717665B1
Authority
KR
South Korea
Prior art keywords
subject
pharmaceutical composition
composition according
therapeutically effective
diosmin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207003115A
Other languages
English (en)
Korean (ko)
Other versions
KR20200051579A (ko
Inventor
로버트 엠. 레비
Original Assignee
프리머스 파머수티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프리머스 파머수티컬즈, 인크. filed Critical 프리머스 파머수티컬즈, 인크.
Publication of KR20200051579A publication Critical patent/KR20200051579A/ko
Application granted granted Critical
Publication of KR102717665B1 publication Critical patent/KR102717665B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020207003115A 2017-07-19 2018-07-18 자가면역 미세혈관 장애의 치료 방법 Active KR102717665B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762534237P 2017-07-19 2017-07-19
US62/534,237 2017-07-19
PCT/US2018/042573 WO2019018455A1 (en) 2017-07-19 2018-07-18 METHODS OF TREATING AUTOIMMUNE MICROVASCULAR DISORDERS

Publications (2)

Publication Number Publication Date
KR20200051579A KR20200051579A (ko) 2020-05-13
KR102717665B1 true KR102717665B1 (ko) 2024-10-14

Family

ID=65016682

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207003115A Active KR102717665B1 (ko) 2017-07-19 2018-07-18 자가면역 미세혈관 장애의 치료 방법

Country Status (12)

Country Link
US (2) US11278517B2 (https=)
EP (2) EP3654965B1 (https=)
JP (1) JP7237962B2 (https=)
KR (1) KR102717665B1 (https=)
CN (1) CN111065389B (https=)
AU (1) AU2018304208B2 (https=)
CA (1) CA3069921C (https=)
ES (1) ES2957742T3 (https=)
HR (1) HRP20231517T1 (https=)
MX (1) MX2020000625A (https=)
PL (1) PL3654965T3 (https=)
WO (1) WO2019018455A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306300A (zh) * 2022-01-04 2022-04-12 上海交通大学医学院附属仁济医院 一种香叶木素的用途及其动物模型的建立方法
WO2026014965A1 (ko) * 2024-07-11 2026-01-15 한국 한의학 연구원 한련초 추출물 유래 화합물을 유효성분으로 함유하는 천포창의 예방, 개선 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208777A1 (en) 2008-04-01 2012-08-16 Les Laboratoires Servier Diosmetin compounds, a process for their preparation and pharmaceutical compositions containing them
US20150164826A1 (en) 2002-08-20 2015-06-18 Philera New Zealand Limited Dosage Forms and Related Therapies
WO2015153648A1 (en) 2014-03-31 2015-10-08 Ingredients By Nature Flavonoid compositions and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1288257B1 (it) * 1996-11-29 1998-09-11 Paoli Ambrosi Gianfranco De Composizione per uso cosmetico,farmaceutico o dietetico a base di un aminozucchero e/o di un acido poliidrossilico

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150164826A1 (en) 2002-08-20 2015-06-18 Philera New Zealand Limited Dosage Forms and Related Therapies
US20120208777A1 (en) 2008-04-01 2012-08-16 Les Laboratoires Servier Diosmetin compounds, a process for their preparation and pharmaceutical compositions containing them
WO2015153648A1 (en) 2014-03-31 2015-10-08 Ingredients By Nature Flavonoid compositions and uses thereof

Also Published As

Publication number Publication date
AU2018304208A1 (en) 2020-02-13
US11844777B2 (en) 2023-12-19
JP7237962B2 (ja) 2023-03-13
PL3654965T3 (pl) 2024-02-26
EP3654965A1 (en) 2020-05-27
CN111065389B (zh) 2023-11-21
KR20200051579A (ko) 2020-05-13
EP4269397A3 (en) 2024-01-31
WO2019018455A1 (en) 2019-01-24
US11278517B2 (en) 2022-03-22
ES2957742T3 (es) 2024-01-24
EP3654965A4 (en) 2021-03-10
AU2018304208B2 (en) 2022-03-17
CA3069921A1 (en) 2019-01-24
JP2020528454A (ja) 2020-09-24
EP3654965C0 (en) 2023-09-06
EP3654965B1 (en) 2023-09-06
US20220168267A1 (en) 2022-06-02
HRP20231517T1 (hr) 2024-03-01
CA3069921C (en) 2022-01-18
US20200147031A1 (en) 2020-05-14
EP4269397A2 (en) 2023-11-01
MX2020000625A (es) 2020-09-28
CN111065389A (zh) 2020-04-24

Similar Documents

Publication Publication Date Title
Peng et al. Andrographolide sulfonate ameliorates lipopolysaccharide-induced acute lung injury in mice by down-regulating MAPK and NF-κB pathways
JP7650929B2 (ja) 成人における焦点てんかんの処置のための合成経皮的カンナビジオール
Cospite Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids.
US6444681B1 (en) Methods and compositions for treating Raynaud's Phenomenon and scleroderma
KR102717665B1 (ko) 자가면역 미세혈관 장애의 치료 방법
EP3247365A1 (en) Novel iodophor composition and methods of use
JP2026021382A (ja) 三環式ヘテロアリール基を有する化合物の用途
JP2024541514A (ja) 進行性線維化を伴う間質性肺疾患を処置するための、新たな治療的組合せ
Schutz et al. Local anaesthetic properties of ambroxol hydrochloride lozenges in view of sore throat
WO1996004013A1 (en) Use of il-6 to treat toxic shock
JP2024543161A (ja) 進行性線維化を伴う間質性肺疾患を治療するための、新たな経口医薬組成物及び投与レジメン
Manhiani et al. IL6 suppression provides renal protection independent of blood pressure in a murine model of salt-sensitive hypertension
Koenig Efficacy and tolerability of felodipine and amlodipine in the treatment of mild to moderate hypertension: a randomised double-blind multicentre trial
JP2022551672A (ja) 乳癌治療法
JP2003055205A (ja) 抗真菌病組成物
Dyck et al. Treatment of duodenal ulceration in the United States
EP3654984A1 (en) Topical treatment for preventing and mitigating skin cytotoxicity due to therapy with tyrosine kinase inhibitors
Martorell-Calatayud et al. Multiple painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea
NILSSON et al. A comparison of 100 mg atenolol and 100 mg metoprolol once a day at rest and during exercise in hypertensives
Cooper et al. The analgesic efficacy of suprofen in periodontal and oral surgical pain
RU2794363C1 (ru) Фармацевтические композиции для лечения инфекционно-воспалительных заболеваний
JP7257091B2 (ja) 認知症の治療及び予防薬
AU2005239799B2 (en) Sustained-release oral molsidomine composition for treating atherosclerosis
RU2684330C1 (ru) Композиции фулвестранта
WO2023085973A1 (ru) Фармацевтические композоции для лечения инфекционно-воспалительных заболеваний

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200131

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210630

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230907

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240716

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241010

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241010

End annual number: 3

Start annual number: 1

PG1601 Publication of registration